pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›PIFELTRO
drug · small molecule
save

PIFELTRO

updated 5mo ago
by $MRK Merck & Co., Inc.🔗 ChEMBL
community read0 votes

🐶 often sniffed alongside

top 8
  • drugDELSTRIGO39 co-mentions · 14 sources
  • tagApproval38 co-mentions · 13 sources
  • drugdoravirine32 co-mentions · 14 sources
  • tagSmall Molecule19 co-mentions · 13 sources
  • drug(doravirine + lamivudine + tenofovir disoproxil fumarate)7 co-mentions · 7 sources
  • drug(doravirine + islatravir hydrate)1 co-mentions · 1 sources
  • tagInfectious Disease1 co-mentions · 1 sources
  • tagPDUFA1 co-mentions · 1 sources

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 1 investigational indication.

targets

Human immunodeficiency virus type 1 reverse transcriptase

all catalysts(0)

nothing on the calendar yet

Trials studying PIFELTRO

  • phase4Efficacy and Safety of Doravirine in the Rapid Initiationrecruitingn=100
  • phase1Single Dose Pharmacokinetics of Doravirine in HIV-infected Pregnant Womencompletedn=7
  • phase4Study on PhArmacokinetics of First liNe Antiretrovirals in Healthy Breastfeeding Volunteerscompletedn=20
  • phase2Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)recruitingn=84
  • EP1Doravirine Versus Integrase Inhibitors on Backbone of Emtricitabine and Tenofovir Alafenamide in HIVcompletedn=26
  • phase3DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 Infectionrecruitingn=610
  • —Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartumcompletedn=205
  • phase2DOR/TDF/3TC Switch With M184V/I in People With Controlled HIV (Drive Off-Road)recruitingn=32

News(1)

  • Merck adds to pharma’s AI push; Roche details MS drug results
    Merck is making a $1 billion investment in a deal with Google Cloud. Elsewhere, Roche pitched its case for a closely watched multiple sclerosis pill and Arcus and Gilead are ending a yearslong alli…
    biopharma_dive · 5mo ago
brand
PIFELTRO
trade names
Doravirine component of delstrigo, Pifeltro
generic
DORAVIRINE
MOA
12.1 Mechanism of Action Doravirine is an antiretroviral drug [see Microbiology (12.4) ].
indication
1 INDICATIONS AND USAGE PIFELTRO ® is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg: with no prior antiretroviral treatment history; OR to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to doravirine [see Clinical Studies (14) ] . PIFELTRO, a non-nucleoside reverse transcriptase inhibitor (NNRTI), is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg: with no prior antiretroviral treatment history, OR to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to doravirine. ( 1 )
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 2h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?